TMC435 Proven Effective for Hepatitis C

Medivir announces positive 48-week interim data from TMC435 hepatitis C Phase IIb study.

Medivir has announced positive results from a Phase IIb study of TMC435 in patients with genotype 1 chronic hepatitis C.

The randomised, placebo-controlled, double-blind study included 462 patients who have relapsed, achieved partial response, or achieved no response to standard of care treatment.

Interim 48-week data revealed that 94% of patients treated with TMC435 showed sustained virologic response, compared to 84% for placebo.

TMC435 treated patients achieved undetectable HCV RNA levels, mild and reversible increases in bilirubin and decrease in mean alanine aminotransferase levels.